osimertinib + omeprazole

**Osimertinib + omeprazole** is a combination of two pharmaceutical drugs: osimertinib, a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) primarily indicated for the treatment of EGFR-mutant non-small cell lung cancer, and omeprazole, a proton pump inhibitor (PPI) used to reduce gastric acid production for conditions like GERD and peptic ulcer disease. The mechanism of osimertinib involves covalently binding and inhibiting mutant (including T790M) and wild-type EGFR to block downstream signaling pathways important for cancer cell proliferation and survival. Omeprazole inhibits the gastric parietal cell H+/K+-ATPase pump, suppressing acid secretion[4][2][6]. Pharmacokinetic drug interaction studies show that coadministration of omeprazole does not significantly alter osimertinib exposure in healthy subjects[7], but preclinical data suggest that PPIs can alter the disposition of orally administered osimertinib (by affecting pH and absorption)[1].

Other names

osimertinib + omeprazole